Lifetime costs, health benefits (per 100,000), and incremental costs effectiveness ratio of combined screening and treatment strategies for various patient ages.

*Population weighted average (white male 44%, white female 45%, black male 5%, black female 6%) for fibrosis distribution: F0 13%, F1 51%, F2 13%, F3 10%, and F4 13%. All incremental cost and QALY are compared to the reference.
ICER = incremental cost-effectiveness ratio; IL-28B = interleukin-28B; QALY = quality-adjusted life-year.
“Dominated” indicates that the strategy costs more and provides fewer benefits than another strategy or a combination of two strategies.

*纤维化分期分布的人群加权平均结果如下：研究队列的人口学构成为白人男性44%、白人女性45%、黑人男性5%、黑人女性6%；纤维化分期占比分别为F0期13%、F1期51%、F2期13%、F3期10%、F4期13%。所有增量成本与质量调整生命年（quality-adjusted life-year，QALY）均以参照干预方案为基准进行对比。
增量成本效果比（incremental cost-effectiveness ratio，ICER）；白细胞介素-28B（interleukin-28B，IL-28B）；质量调整生命年（quality-adjusted life-year，QALY）。
“被占优策略（dominated）”指相较于另一项单一干预策略或两项策略的联合方案，该策略成本更高且获益更少。